John McGinty, MD
Cardiovascular Disease · Richmond, INNPI 1003845371
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Novartis at 59.0% of the total. Reporting peaked in 2019 at $10,800 and has fallen 91.0% since, to $971 in 2025.
Across 431 payments — averaging $39.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$10K
- E.r. Squibb & Sons, L.L.C.$1K
- Abbott$955
- AstraZeneca$851
- Johnson & Johnson$609
- Pfizer$599
- plus $3K from 30 others
Across 703 payments — averaging $5280.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1M
- American Regent$446K
- Boehringer Ingelheim International GmbH$379K
- Eli Lilly$263K
- Boehringer Ingelheim Pharma GmbH & Co.kg$218K
- AstraZeneca$204K
- plus $1.2M from 14 others
What the payments were for
- Speaking & faculty fees$9,91058%
- Travel & lodging$350%
- Food & beverage$7,02041%
- Education$1161%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 77 | $10,076 |
| E.r. Squibb & Sons, L.L.C. | 17 | $1,172 |
| Abbott | 55 | $955 |
| AstraZeneca | 44 | $851 |
| Johnson & Johnson | 41 | $609 |
| Pfizer | 43 | $599 |
| Amgen | 23 | $341 |
| Boston Scientific | 11 | $280 |
| Merck | 16 | $269 |
| Boehringer Ingelheim | 17 | $256 |
| Sanofi-aventis U.S. LLC | 16 | $244 |
| Heartflow, Inc. | 7 | $163 |
| Novo Nordisk | 6 | $159 |
| Inari Medical, Inc. | 2 | $145 |
| Amarin Pharma, Inc. | 9 | $141 |
| Scpharmaceuticals Inc. | 7 | $135 |
| Alnylam Pharmaceuticals Inc. | 4 | $83 |
| Lexicon Pharmaceuticals, Inc. | 4 | $66 |
| Abiomed | 2 | $65 |
| Kowa Pharmaceuticals America, Inc. | 5 | $56 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $44 |
| Philips North America LLC | 2 | $41 |
| Bayer | 2 | $35 |
| Chiesi USA, Inc. | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Medtronic | 1 | $30 |
| Tactile Systems Technology Inc | 2 | $30 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Angiodynamics, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Impulse Dynamics (USA) Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Gilead | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$8,960
- ELIQUIS$950
- FLOWTRIEVER CATHETER, S$131
- CT THROMBECTOMY SYSTEM KIT$131
- AVEIR$109
- WATCHMAN Access System$103
How this compares
$17,081 in reported general payments places this provider in the 85th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 865 | $824,566 |
| XareltoRivaroxaban | 301 | $274,006 |
| JardianceEmpagliflozin | 217 | $197,183 |
| EntrestoSacubitril/Valsartan | 127 | $143,370 |
| Repatha SureclickEvolocumab | 169 | $138,650 |
| FarxigaDapagliflozin Propanediol | 104 | $88,641 |
| BrilintaTicagrelor | 95 | $66,952 |
| MultaqDronedarone Hcl | 61 | $58,913 |
| Praluent PenAlirocumab | 51 | $44,644 |
| VascepaIcosapent Ethyl | 24 | $18,524 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 65 | $15,228 |
| Ranolazine ErRanolazine | 130 | $12,149 |
| Prasugrel Hcl | 90 | $11,993 |
| Atorvastatin Calcium | 1,022 | $8,608 |
| Icosapent Ethyl | 28 | $7,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $599 | $824,566865 claims |
| Johnson & JohnsonXarelto | $609 | $274,006301 claims |
| Boehringer IngelheimJardiance, Synjardy | $256 | $203,128228 claims |
| AstraZenecaFarxiga, Brilinta | $851 | $155,593199 claims |
| NovartisEntresto | $10,076 | $143,370127 claims |
| Sanofi-aventis U.S. LLCMultaq | $244 | $58,91361 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Richmond
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.